Mosquirix targets the Plasmodium falciparum parasite, the most deadly malaria parasite globally and the most prevalent in Africa. The vaccine induces an immune response against the circumsporozoite protein of the parasite, aiming to prevent it from infecting liver cells where it multiplies and initiates symptom onset.
